GHRH analogue · early human endocrine studies
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, usually abbreviated GHRH. GHRH signals the pituitary gland to release growth hormone, which is linked to downstream IGF-1 signalling.
How does CJC-1295 work?
The long-acting compound studied as CJC-1295 was designed to extend the signal’s duration. Names used in product marketing can blur distinctions between long-acting preparations and differently modified GHRH peptides. [1]
What does the research show?
A 2006 paper reported two short, randomised, placebo-controlled studies in healthy adults. It measured increases in growth hormone and IGF-1 after CJC-1295. These were endocrine and pharmacokinetic outcomes. [1]
What the evidence does not establish
Short-term hormone changes do not establish long-term muscle, sleep, recovery or longevity benefits. The findings should not be applied to a differently identified substance labelled with similar wording, including informal no-DAC terminology.
Safety questions to discuss
Confirm the exact identity used in any cited study. Monitoring questions should address the hormone pathway and the individual’s medical context, rather than assuming that a research label proves suitability. [2]
Frequently asked questions
Is CJC-1295 the same as growth hormone?
No. It is a GHRH analogue studied for stimulating the body’s hormone-release pathway.
Do higher GH or IGF-1 results establish improved health?
No. A biomarker change alone does not demonstrate a meaningful clinical benefit.
Sources and further reading
- CJC-1295 in healthy adults — two randomised trials, 2006
- GH pulsatility during CJC-1295 stimulation — human study, 2006
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.